The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer.
 
Harri Jarvelainen
Employment - Lisata; Ractigen Therapeutics
Leadership - Lisata; Ractigen Therapeutics
Stock and Other Ownership Interests - Lisata
 
Wei-Hsiang Lin
Employment - Ractigen Therapeutics
Stock and Other Ownership Interests - Ractigen Therapeutics
 
Moorim Kang
Employment - Ractigen Therapeutics
Stock and Other Ownership Interests - Ractigen Therapeutics
 
Xiaojie Zhou
Employment - Ractigen Therapeutics
 
Robert F. Place
Employment - Ractigen Therapeutics
Leadership - Ractigen Therapeutics
Stock and Other Ownership Interests - Ractigen Therapeutics
 
Long-Cheng Li
Employment - Ractigen Therapeutics
Leadership - Ractigen Therapeutics
Stock and Other Ownership Interests - Ractigen Therapeutics